Table 7.
Comparison of some parameters, treatment options, and disease-related complications between the current study and some other related studies.
| Parameter | Current study (n = 159) % | Lebanon (n = 73) 2000 [28] | Optimal care (n = 584) 2010 [34] | Iran (n = 153) 2011 [36] | Basra (n = 80) 2013 [35] | Dohuk (n = 74) 2014 [17] | Italy (n = 70) 2014 [37] | Sri Lanka (n = 50) 2019 [38] |
|---|---|---|---|---|---|---|---|---|
| Splenectomized | 32.7 | 59 | 55.7 | 46.9 | ∗ | 23.0 | 49 | 12.0 |
| Serum ferritin (μg/L) | ||||||||
| <1000 | 76.7 | ∗ | 64.4 | ∗ | 55 | 67.6 | ∗ | ∗ |
| >1000 | 23.3 | 35.6 | 45 | 32.4 | ||||
| Treatment | ||||||||
| Transfusion | ||||||||
| Never transfused | 20.8 | 28.8 | 23.8 | 27.5 | 21.2 | 32.4 | 53 | 4.0 |
| Occasionally | 47.2 | 58.9 | 24.5 | 45.5 | 78.8 | 51.4 | 34 | 42 |
| Regularly | 32.1 | 12.3 | 51.7 | 27 | 16.2 | 13 | 44 | |
| Iron chelation | 39.6 | ∗ | 47.5 | ∗ | ∗ | 14.9 | 56 | 46 |
| Hydroxyurea | 47.2 | ∗ | 34.6 | ∗ | ∗ | 2.7 | 16 | ∗ |
| Complications | ||||||||
| Facial deformity | 62.3 | 44 | ∗ | ∗ | ∗ | 73 | ∗ | ∗ |
| Osteoporosis | 28.3 | ∗ | 22.9 | 53 | 30.0 | ∗ | 49 | ∗ |
| Growth retardation (height < 3rd percentile) | 27.8 | ∗ | ∗ | ∗ | 42.5 | 31.3 | ∗ | 26.7 |
| Subclinical hypothyroidism | 16.8 | ∗ | ∗ | ∗ | ∗ | ∗ | 33.3 | ∗ |
| Cholelithiasis | 13.8 | ∗ | 17.1 | 9.8 | 2.5 | ∗ | ∗ | 10.0 |
| PHT | 11.3 | ∗ | 11 | 23.5 | 5.0 | 20.4 | ∗ | 33.3 |
| Abnormal liver function | 7.5 | ∗ | 9.8 | 29.3 | 13.5 | ∗ | ∗ | |
∗Not mentioned in the study.